Article Text

Download PDFPDF

Exhaled nitric oxide in sarcoidosis
Free
  1. M L Wilsher1,
  2. W Fergusson1,
  3. D Milne1,
  4. A U Wells2
  1. 1Green Lane Respiratory Services, Auckland City Hospital, Auckland, New Zealand
  2. 2Royal Brompton Hospital, London, UK
  1. Correspondence to:
    Dr M L Wilsher
    Green Lane Respiratory Services, Auckland City Hospital, Auckland 1, New Zealand; mwilsheradhb.govt.nz

Abstract

Background: Increased production of nitric oxide (NO) by the lower respiratory tract is viewed as a marker of airway inflammation in asthma and bronchiectasis. NO is a potentially important immune modulator, inhibiting the release of several key pro-inflammatory cytokines. As sarcoidosis is characterised by granulomatous airway inflammation, we hypothesised that exhaled NO levels might be raised in sarcoidosis and correlate with the morphological extent and functional severity of disease.

Methods: Fifty two patients with sarcoidosis (29 men) of mean age 42 years underwent thin section computed tomography (CT), pulmonary function tests, and measurement of exhaled NO.

Results: Exhaled NO levels (median 6.8 ppb, range 2.4–21.8) did not differ significantly from values in 44 control subjects, and were not related to the extent of individual CT abnormalities or the level of pulmonary function impairment.

Conclusion: Exhaled NO levels are not increased in pulmonary sarcoidosis.

  • eNO, exhaled nitric oxide
  • FEF25–75, mean forced expiratory flow during middle half of FVC
  • FEV1, forced expiratory volume in 1 second
  • FVC, forced vital capacity, FRC, functional residual capacity
  • RV, residual volume, TLC, total lung capacity, Tlco, carbon monoxide lung transfer factor
  • sarcoidosis
  • exhaled nitric oxide
  • computed tomography
  • pulmonary function tests

Statistics from Altmetric.com

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Footnotes

  • The chemiluminescence analyser was purchased with funds from Lottery Health Research.

  • Competing interests: none declared